作者: Barbara Blauhut , Wolfgang Harringer , Peter Bettelheim , Jan Eva Doran , Peter Späth
DOI: 10.1016/S0022-5223(12)70192-7
关键词:
摘要: Aprotinin reduces blood loss after cardiopulmonary bypass, but may sensitize recipients and is expensive. Tranexamic acid, a synthetic antifibrinolytic, has less disadvantages, opinions differ regarding its efficacy. We studied three groups of patients undergoing bypass for coronary disease: aprotinin (total dose 4.2 × 106 kallikrein inhibiting units, n =14), tranexamic acid 20 mg/kg body weight, =15), nonmedicated controls (n =14) during 24 hours bypass. Compared with controls, reduced loss, the number requiring transfusions, mean transfused red cell units (all p